Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC

Video content above is prompted by the following questions:

1. B. Ideate-Lung02: Phase 3 Clinical Trial of Ifinatamab Deruxtecan vs TPC in Relapsed ES-SCL [TPS8126]
   1. Please share your perceptions of the potential for durable response to ifinatamab, a B7-H3-directed ADC in patients with previously treated, relapsed SCLC.
   2. How encouraging is an ORR of 52.4%, a 5.9-month median DoR, and a 12.2-month
   3. OS after a median 2 prior lines of therapy as reported in the Phase I/II trial?
   4. Currently, can you assay B7-H3 to determine individual expression levels?
   5. How does a treatment schedule of 12 mg/kg IV Q3W compare with that of:
   6. amrubicin [(Calsed) aminoanthracycline]: 45mg/m2 IV Infusion QD x 3 days Q3W [Japan]
   7. topotecan [(Hycamtin) topoisomerase inhibitor]: 1.5 mg/m2 IV infusion QD, Days 1-5 Q3W
   8. lurbinectedin [(Zepzelca) alkylating agent]: 3.2 mg/m2IV infusion Q3W
2. What is the potential for immunogenicity with this ADC, and which treatment-related adverse events would most concern you?